Zymeworks (ZYME) Non-Current Deffered Revenue (2021 - 2026)
Zymeworks recorded quarterly Non-Current Deffered Revenue of $14.6 million in Q1 2026, little changed quarter-over-quarter from $14.6 million in Q4 2025, and little changed year-over-year from $14.6 million in Q1 2025.
Zymeworks' Non-Current Deffered Revenue history runs 6 years deep, the most recent figure standing at $14.6 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue changed 0.01% year-over-year to $14.6 million; the TTM figure through Mar 2026 stood at $14.6 million (changed 0.01% YoY), while the FY2025 annual figure was $14.6 million, changed 0.01% from the prior year.
- Non-Current Deffered Revenue came in at $14.6 million for Q1 2026 at Zymeworks, roughly flat from $14.6 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $32.9 million in Q3 2022 to a low of $14.6 million in Q4 2025.
- A 5-year average of $23.9 million and a median of $30.6 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue increased 7.69% in 2023 and plunged 55.66% in 2024, its largest moves.
- Zymeworks' Non-Current Deffered Revenue stood at $30.6 million in 2022, then increased by 7.69% to $32.9 million in 2023, then slumped by 55.66% to $14.6 million in 2024, then retreated by 0.01% to $14.6 million in 2025, then changed by 0.0% to $14.6 million in 2026.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $14.6 million, $14.6 million, and $14.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 14.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.61 Mn |
| Dec 31, 2025 | 14.61 Mn |
| Sep 30, 2025 | 14.61 Mn |
| Jun 30, 2025 | 14.61 Mn |
| Mar 31, 2025 | 14.61 Mn |
| Dec 31, 2024 | 14.61 Mn |
| Sep 30, 2024 | 14.61 Mn |
| Jun 30, 2024 | 32.94 Mn |
| Mar 31, 2024 | 32.94 Mn |
| Dec 31, 2023 | 32.94 Mn |
| Sep 30, 2023 | 32.94 Mn |
| Jun 30, 2023 | 30.59 Mn |
| Mar 31, 2023 | 30.59 Mn |
| Dec 31, 2022 | 30.59 Mn |
| Sep 30, 2022 | 32.94 Mn |
| Dec 31, 2021 | 32.94 Mn |